A study on the immune response and safety elicited by a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccine against influenza in adults aged 60 years and above

Trial Identifier: 214488
Sponsor: GlaxoSmithKline
Start Date: April 2021
Primary Completion Date: September 2021
Study Completion Date: February 2022
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
New Zealand Auckland, New Zealand, 1701
New Zealand Auckland, New Zealand, 1010
New Zealand Christchurch, New Zealand, 8011
New Zealand Havelock North, New Zealand, 4130
New Zealand Paraparaumu, New Zealand, 5032
New Zealand Tauranga, New Zealand, 3001
New Zealand Wellington, New Zealand, 6242
Panama Panama, Panama, 1001
Panama, Panamá Ciudad de Panama, Panamá, Panama, 7099
Panama, Panamá Panama, Panamá, Panama, 0801
Panama, Panamá Panama, Panamá, Panama, 7219
Panama, Panamá Panama, Panamá, Panama, 7002
South Africa, Gauteng Boksburg, Gauteng, South Africa, 1459
South Africa, Mpumalanga Middelburg, Mpumalanga, South Africa, 1055